全文获取类型
收费全文 | 151篇 |
免费 | 4篇 |
专业分类
儿科学 | 6篇 |
妇产科学 | 2篇 |
基础医学 | 10篇 |
临床医学 | 6篇 |
内科学 | 34篇 |
皮肤病学 | 5篇 |
神经病学 | 4篇 |
特种医学 | 2篇 |
外科学 | 47篇 |
综合类 | 3篇 |
预防医学 | 19篇 |
眼科学 | 1篇 |
药学 | 6篇 |
肿瘤学 | 10篇 |
出版年
2023年 | 4篇 |
2021年 | 4篇 |
2019年 | 1篇 |
2018年 | 1篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2014年 | 2篇 |
2013年 | 3篇 |
2012年 | 6篇 |
2011年 | 10篇 |
2010年 | 4篇 |
2009年 | 5篇 |
2008年 | 16篇 |
2007年 | 15篇 |
2006年 | 12篇 |
2005年 | 9篇 |
2004年 | 7篇 |
2003年 | 8篇 |
2002年 | 4篇 |
2000年 | 5篇 |
1999年 | 2篇 |
1996年 | 2篇 |
1995年 | 1篇 |
1994年 | 1篇 |
1993年 | 1篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1986年 | 3篇 |
1984年 | 2篇 |
1983年 | 1篇 |
1982年 | 1篇 |
1981年 | 1篇 |
1978年 | 3篇 |
1960年 | 1篇 |
1959年 | 1篇 |
1922年 | 1篇 |
1920年 | 1篇 |
1917年 | 1篇 |
1912年 | 1篇 |
1911年 | 1篇 |
1910年 | 1篇 |
1908年 | 3篇 |
排序方式: 共有155条查询结果,搜索用时 15 毫秒
151.
152.
Ohne ZusammenfassungBericht an das Lister-Institut und den Medical Research Council, London.Mit 1 Textabbildung 相似文献
153.
154.
Faiez Zannad Jacqueline Alikhaani Sadegh Alikhaani Javed Butler Jason Gordon Klaus Jensen Rani Khatib Lorenzo Mantovani Robin Martinez Wanda F. Moore Masahiro Murakami Lothar Roessig Norman Stockbridge Harriette G.C. Van Spall Clyde Yancy John A. Spertus 《European journal of heart failure》2023,25(4):478-487
There are many consequences of heart failure (HF), including symptoms, impaired health-related quality of life (HRQoL), and physical and social limitations (functional status). These have a substantial impact on patients' lives, yet are not routinely captured in clinical trials. Patient-reported outcomes (PROs) can quantify patients' experiences of their disease and its treatment. Steps can be taken to improve the use of PROs in HF trials, in regulatory and payer decisions, and in patient care. Importantly, PRO measures (PROMs) must be developed with involvement of patients, family members, and caregivers from diverse demographic groups and communities. PRO data collection should become more routine not only in clinical trials but also in clinical practice. This may be facilitated by the use of digital tools and interdisciplinary patient advocacy efforts. There is a need for standardization, not only of the PROM instruments, but also in procedures for analysis, interpretation and reporting PRO data. More work needs to be done to determine the degree of change that is important to patients and that is associated with increased risks of clinical events. This ‘minimal clinically important difference’ requires further research to determine thresholds for different PROMs, to assess consistency across trial populations, and to define standards for improvement that warrant regulatory and reimbursement approvals. PROs are a vital part of patient care and drug development, and more work should be done to ensure that these measures are both reflective of the patient experience and that they are more widely employed. 相似文献
155.
Suzanne Oskouie Faith Michael Sera Whitelaw Biykem Bozkurt Gregg C. Fonarow Harriette G.C. Van Spall 《European journal of heart failure》2023,25(10):1842-1848